Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$5.20 USD
-0.15 (-2.80%)
Updated Apr 26, 2024 03:09 PM ET
After-Market: $5.11 -0.09 (-1.73%) 7:28 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Aprea Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 113 | 37 | 53 | 30 |
Income After Depreciation & Amortization | -15 | -113 | -37 | -53 | -30 |
Non-Operating Income | 1 | 1 | 0 | -1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -14 | -113 | -37 | -53 | -28 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -113 | -37 | -53 | -28 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -113 | -37 | -53 | -28 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -113 | -37 | -53 | -29 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -15 | -113 | -37 | -53 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.62 | 1.66 | 1.06 | 1.06 | 0.30 |
Diluted EPS Before Non-Recurring Items | -3.95 | -31.75 | -34.80 | -50.60 | -93.40 |
Diluted Net EPS (GAAP) | -3.95 | -67.99 | -34.80 | -50.60 | -93.40 |
Fiscal Year end for Aprea Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.01 | 0.32 | 0.25 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.01 | 0.32 | 0.25 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.69 | 3.84 | 3.90 | 4.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.68 | -3.52 | -3.65 | -4.63 |
Non-Operating Income | NA | 0.23 | 0.32 | 0.39 | 0.24 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -3.44 | -3.20 | -3.26 | -4.38 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.44 | -3.20 | -3.26 | -4.38 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.44 | -3.20 | -3.26 | -4.38 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.74 | 3.74 | 3.73 | 3.26 |
Diluted EPS Before Non-Recurring Items | NA | -0.92 | -0.86 | -0.87 | -1.34 |
Diluted Net EPS (GAAP) | NA | -0.88 | -0.86 | -0.87 | -1.34 |